Market Overview
The Saudi Arabia intravenous solution market size increased from USD 151.4 Million in 2025 to USD 158.0 Million in 2026 and is projected to reach USD 222.3 Million by 2034, growing at a CAGR of 4.36% during 2026-2034. This growth is driven by rising prevalence of chronic diseases requiring long-term intravenous nutritional therapy, rapid healthcare infrastructure expansion under Vision 2030, growing critical care and oncology patient volumes demanding total parenteral nutrition, and increasing demand from Hajj and Umrah medical services. Total parenteral nutrition commands 62.8 percent market share reflecting widespread deployment across ICUs and specialized care units. Carbohydrates lead nutrient segment at 29.4 percent as primary energy substrates.
How Vision 2030 Healthcare Expansion and Parenteral Nutrition Demand are Reshaping the Future of Saudi Arabia Intravenous Solution Market:
- Vision 2030 healthcare infrastructure investments expanding ICU capacity and hospital bed numbers nationwide.
- Rising chronic disease prevalence including diabetes and cardiovascular conditions driving parenteral nutrition demand.
- Growing critical care patient volumes in expanded intensive care units requiring high-volume IV solution utilization.
- Hajj and Umrah pilgrimage medical services creating unique seasonal IV solution demand surges.
- Multi-chamber bag technology replacing bedside compounding improving sterility and reducing preparation time.
- Domestic pharmaceutical manufacturing incentives under Vision 2030 attracting IV solution production investment.
Grab a sample PDF of this report: https://www.imarcgroup.com/saudi-arabia-intravenous-solution-market/requestsample
Market Growth Factors
Rising chronic disease prevalence represents fundamental driver of Saudi Arabia intravenous solution market expansion. Saudi Arabia carries one of world’s highest metabolic chronic disease burdens with diabetes prevalence at 18.5 percent of adult population and hypertension affecting 24.5 percent of adults aged 18 years and above. Each hospitalization for diabetes complication, renal failure episode, or acute cardiac event generates demand for intravenous solutions including glucose infusions and electrolyte replacements. Critically ill patients requiring metabolic support drive total parenteral nutrition prescription volumes. Expanded hospitalization rates create proportional intravenous solution procurement increases.
Vision 2030 healthcare infrastructure expansion fundamentally transform Saudi Arabia intravenous solution market dynamics and capacity. Saudi Arabia planned USD 66 billion healthcare infrastructure investment under Vision 2030 while raising private sector participation from 40 percent to 65 percent. New hospital construction and ICU bed capacity expansion mandate requirements establish 8-15 percent of total hospital beds as intensive care units. Each new ICU bed generates estimated SAR 50,000-80,000 (USD 13,000-21,000) annual intravenous solution procurement. Ministry of Health healthcare access and quality digital solution initiatives create sustained intravenous solution demand expansion.
Hajj and Umrah pilgrimage medical services generate unique seasonal intravenous solution demand surge supporting market growth. Saudi Arabia recorded 18.5 million pilgrims in 2024 comprising 16.92 million Umrah arrivals and 1.61 million Hajj pilgrims. Pilgrims requiring medical services including high-volume intravenous fluid and electrolyte replenishment for heat exhaustion, dehydration, and acute medical emergencies consume significant intravenous solution volumes. Pilgrimage-related demand creates concentrated regional utilization at Makkah and Madinah hospitals without parallel in other markets. Government healthcare capacity planning includes Hajj surge demand in infrastructure development.
Market Segmentation
Type Insights:
- Total Parenteral Nutrition
- Partial Parenteral Nutrition
Nutrients Insights:
- Carbohydrates
- Amino Acids
- Salts and Electrolytes
- Vitamins
- Minerals
Regional Insights:
- Northern and Central Region
- Western Region
- Eastern Region
- Southern Region
Key Players
- Fresenius SE & Co. KGaA
- Baxter International, Inc.
- B. Braun SE
- ICU Medical Inc.
- Bayer Healthcare
- Merck KGaA
- Hikma Pharmaceuticals
- Gulf Pharma Limited
Recent Development and News
- January 2025: US-based Akkad Holdings announces a USD 200 million investment to establish an intravenous fluid production plant in King Abdullah Economic City under Shamekh IV Solutions, targeting global supply shortages and local self-sufficiency.
- January 2026: The Saudi Minister of Industry inaugurates new production lines in Jeddah’s Second Industrial City focused on local manufacturing of intravenous solutions and single-use eye drops.
- October 2024: IV ONE launches in Riyadh as Saudi Arabia’s first dedicated outpatient infusion therapy centre, providing specialised IV treatments for chronic illness and nutrient-deficient patients.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201-971-6302